NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$29.82
+1.05 (+3.65%)
Close of Nov 06, 2026 · end-of-day data
SDGR 8-K filings in 2024
Every material Form 8-K Schrödinger filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Schrödinger reported third-quarter 2024 total revenue of $35.3 million, down from $42.6 million a year earlier, while software revenue rose 10%. The net loss narrowed to $38.1 million from $62.0 million, mainly due to changes in the fair value of equity investments, and the company raised the low end of its 2024 software revenue growth guidance. The company also said Novartis will pay $150 million upfront under a new collaboration.
Total revenue fell 17% to $35.3 million; software revenue rose 10% to $31.9 million, while drug discovery revenue fell to $3.4 million from $13.7 million.
Software gross margin decreased to 73% from 76%; operating expenses rose to $86.2 million from $79.8 million.
2024 software revenue growth guidance is now 8% to 13%; drug discovery revenue guidance is $20 million to $30 million.
Novartis will pay Schrödinger $150 million upfront under a multi-target collaboration announced November 12, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Schrödinger filing is on SEC EDGAR ↗. 8-K briefs of other companies →